KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $2.2 million.

  • Rigel Pharmaceuticals' Depreciation & Amortization (CF) fell 1.31% to $603,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 26.13%. This contributed to the annual value of $2.2 million for FY2024, which is 79.97% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $2.2 million for FY2024, which was up 79.97% from $1.2 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $2.2 million in FY2024 and a low of $706,000 during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $1.5 million, with a median of $1.2 million in 2023.
  • In the last 5 years, Rigel Pharmaceuticals' Depreciation & Amortization (CF) decreased by 14.11% in 2022 and then soared by 79.97% in 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $706,000 in 2020, then surged by 64.59% to $1.2 million in 2021, then decreased by 14.11% to $998,000 in 2022, then grew by 24.05% to $1.2 million in 2023, then surged by 79.97% to $2.2 million in 2024.